Stockscreener 앱 받기
2.59
0.77%
-0.02
시장 영업 전:
2.76
0.17
+6.56%
Rocket Pharmaceuticals Inc 주식(RCKT)의 최신 뉴스
RCKT Stock Dives Despite Gene Therapy Approval — Wall Street Dismisses Sell-Off - Stocktwits
Rocket Pharmaceuticals Advances Danon Disease Gene Therapy Trial With FDA Alignment - streetwisereports.com
Rocket Pharmaceuticals, Inc. (RCKT) Stock Price, News, Quote & History - Yahoo! Finance Canada
Rocket Pharmaceuticals (RCKT) Gets FDA Alignment on Heart Drug Trial. Can it Ease Safety Concerns? - Yahoo Finance
Rocket Pharmaceuticals stock holds focus on clinical milestones - AD HOC NEWS
Have Insiders Sold Rocket Pharmaceuticals Shares Recently? - simplywall.st
RCKT Aligns With FDA on Completing Phase II Study in Danon Disease - The Globe and Mail
Needham Upgrade Boosts Rocket Pharmaceuticals (RCKT) on FDA Tria - GuruFocus
Rocket Pharma stock upgraded at Needham (RCKT:NASDAQ) - Seeking Alpha
Leerink Partners Maintains Rocket Pharmaceuticals(RCKT.US) With Hold Rating - Moomoo
RCKT Reiterates by Wedbush -- Price Target Maintained at $15 - GuruFocus
Rocket Pharmaceuticals’ FDA Decision Clears ‘Meaningful Regulatory Overhang,’ Says Needham — Sees 150% Upside Potential In RCKT Stock - Yahoo Finance
Needham Upgrades Rocket Pharmaceuticals (RCKT) to Buy After FDA Trial Design Approval - GuruFocus
Rocket Pharmaceuticals general counsel sells $256,463 in RCKT shares By Investing.com - Investing.com South Africa
Rocket Pharmaceuticals (RCKT) counsel sells shares to cover RSU tax bill - stocktitan.net
Former Rocket Pharmaceuticals (RCKT) executive plans stock sale tied to equity award taxes - Stock Titan
Rocket Pharma Jumps as FDA Backs 12-Patient Pivotal Plan for Danon Gene Therapy - finance.biggo.com
Rocket Pharma gets FDA alignment on Danon disease trial By Investing.com - Investing.com Nigeria
RCKT Maintained by Chardan Capital -- Price Target Stays at $11. - GuruFocus
Rocket Pharmaceuticals Secures FDA Agreement on RP-A501 Phase 2 Trial for Danon Disease - Kalkine Media
Rocket Pharmaceuticals Shares Rise 8% After FDA Alignment on Danon Disease Trial - Yahoo Finance
Why is Rocket Pharmaceuticals stock down 5% today? By Investing.com - Investing.com Canada
Rocket Pharma Gets FDA Alignment On This Key Trial -- A Look At Some Key Highlights - Yahoo Finance
Form 8K Rocket Pharmaceuticals Inc For: 15 September By Investing.com - Investing.com Nigeria
Rocket Pharmaceuticals (RCKT) Advances Phase 2 Trial with FDA Ag - GuruFocus
Rocket Pharmaceuticals Says FDA Confirms Path to Complete Phase 2 Danon Disease Trial - marketscreener.com
Rocket Pharma gets FDA alignment on Danon disease trial - Investing.com
RCKT 8-K FilingsRocket Pharmaceuticals, Inc. SEC 8-K - Stock Titan
Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease - businesswire.com
Former Rocket Pharmaceuticals (RCKT) officer plans to sell 6,857 shares under an SEC trading rule - Stock Titan
Rocket Pharma (RCKT) executive plans sale of 75K shares tied to vested stock taxes - Stock Titan
Former Rocket Pharma (NASDAQ: RCKT) exec plans stock sale - Stock Titan
Rocket Pharmaceuticals Inc. (RCKT) Key Financial Ratios – Valuation, Profitability & More - Value Research
Rocket Pharmaceuticals at cantor healthcare conference: cardiomyopathy focus By Investing.com - Investing.com Canada
Rocket Pharmaceuticals at cantor healthcare conference: cardiomyopathy focus - Investing.com
Rocket Pharmaceuticals (RCKT) Up 6% Since Last Earnings Report: Can It Continue? - Yahoo Finance
RCKT News | ROCKET PHARMACEUTICALS INC (NASDAQ:RCKT) - ChartMill
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences - Yahoo Finance
Rocket Pharma (NASDAQ: RCKT) to pull 2026 warrant listing - Stock Titan
Chardan assumes Rocket Pharmaceuticals stock coverage with buy rating By Investing.com - Investing.com Nigeria
Chardan assumes Rocket Pharmaceuticals stock coverage with buy rating - Investing.com
Rocket Pharmaceuticals (RCKT) Jumps 6.6% to $3.86 as Buyers Defend Key Support LevelGap Up Stocks - vinanet.vn
Rocket Pharmaceuticals (RCKT) Surges 6.6% to $3.86 as Gene Therapy Stock Tests Key ResistanceJelly Roll Trade - careplusvn.com
New Jersey's Rocket Pharma Strikes New Pay Deal For Its GC - Law360
Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations - GuruFocus
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Rocket Pharmaceuticals general counsel Martin Wilson sells $2,133 in stock By Investing.com - Investing.com South Africa
1.73%
1.36%
자본화:
|
볼륨(24시간):